Related references
Note: Only part of the references are listed.Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis
Heather Landau et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis
Brian Lilleness et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
Faye A. Sharpley et al.
HAEMATOLOGICA (2020)
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
Vaishali Sanchorawala et al.
BLOOD (2020)
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis
Murielle Roussel et al.
BLOOD (2020)
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
Christoph R. Kimmich et al.
BLOOD (2020)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis
Oliver C. Cohen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
Suzanne Lentzsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
Rahma Warsame et al.
BLOOD CANCER JOURNAL (2020)
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
Surbhi Sidana et al.
BLOOD CANCER JOURNAL (2020)
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression
Marco Basset et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis
Andrew Staron et al.
BLOOD ADVANCES (2020)
Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
Brian Lilleness et al.
BLOOD (2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Richa Manwani et al.
BLOOD (2019)
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis
Richa Manwani et al.
HAEMATOLOGICA (2018)
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
M. Hasib Sidiqi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis
Richa Manwani et al.
HAEMATOLOGICA (2018)
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies
Giovanni Palladini et al.
BLOOD (2018)
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
E. Muchtar et al.
LEUKEMIA (2017)
The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic
Paolo Milani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore et al.
CIRCULATION (2016)
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
Vaishali Sanchorawala et al.
BLOOD (2015)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
Tilmann Bochtler et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis
Luisa Diomede et al.
BLOOD (2014)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis
Brendan M. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
Tilmann Bochtler et al.
BLOOD (2008)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
